Compared with those who took no IL‐1 blockage, patients taking IL‐1 blockage experienced a decreased risk of overall MACE (RR 0.88, 95% CI 0.82‐0.94), unstable angina (RR 0.80, 95% CI 0.66‐0.98), and breakthrough or recurrence of heart failure (RR 0.44, 95% CI 0.22‐0.87). This evidence concerns the gene IL1A and heart failure.